Eat weight loss pill advice is something many people search for, but knowing how to use these medicines safely and effectively requires more than a quick online search. In the UK, licensed weight loss medications — including orlistat and GLP-1 receptor agonists such as semaglutide (Wegovy) — work through distinct mechanisms and are prescribed under specific NICE eligibility criteria. Used correctly alongside dietary changes and physical activity, they can form part of a structured, clinically supervised weight management plan. This article explains how these medicines work, how to take them safely, what to eat whilst using them, and what side effects to watch for.

How weight loss pills work and who they are suitable for

Weight loss medications work through several distinct pharmacological mechanisms, depending on the specific drug prescribed. The most commonly used options in the UK include orlistat, which inhibits pancreatic lipase enzymes in the gut, thereby reducing the absorption of dietary fat by approximately 30%. More recently, glucagon-like peptide-1 (GLP-1) receptor agonists — such as semaglutide (Wegovy) and liraglutide (Saxenda) — have become available as licensed weight management treatments. These are administered by subcutaneous injection (semaglutide once weekly; liraglutide once daily), not as oral tablets. They mimic the action of a naturally occurring gut hormone, slowing gastric emptying, reducing appetite, and promoting a feeling of fullness after eating.^[3][4]

Eligibility for weight loss medication in the UK depends on the specific medicine and is determined by NICE guidance and individual clinical assessment:

• Orlistat is generally considered for adults with a BMI of 30 kg/m² or above, or a BMI of 28 kg/m² or above in the presence of weight-related comorbidities such as type 2 diabetes or hypertension.

• Semaglutide (Wegovy) is recommended by NICE for use within specialist Tier 3 weight management services for adults who meet specific eligibility criteria, including a higher BMI threshold and at least one weight-related comorbidity.^[1][3] Under current NICE guidance, treatment is limited to a maximum of two years. Commissioning arrangements may vary across England.

• Liraglutide (Saxenda) has its own eligibility criteria and is also intended for use alongside lifestyle interventions.

It is important to note that BMI thresholds for assessing health risk may be lower for people from some ethnic backgrounds; clinicians will take this into account during assessment.^[2]

These medications are intended to complement — not replace — lifestyle changes, and are typically prescribed as part of a structured weight management programme that includes dietary advice, physical activity, and behavioural support.^[2][4] They are not appropriate for individuals who are pregnant, breastfeeding, or have certain underlying medical conditions.

Patients should only use weight loss medicines that are licensed and approved by the MHRA. There is a significant risk associated with purchasing unlicensed, compounded, or counterfeit GLP-1 injection pens online; these products have not been assessed for safety or efficacy and should be avoided. A thorough clinical assessment by a GP or specialist is essential before starting any weight loss treatment.

How to take weight loss medication safely

Taking weight loss medication safely requires careful adherence to prescribing instructions and ongoing clinical supervision.

Orlistat is taken as a 120 mg capsule with each main meal containing fat — up to three times daily.^[4] It should not be taken if a meal is skipped or contains no fat. The over-the-counter version, Alli (60 mg), is available from pharmacies for adults with a BMI of 28 or above, though pharmacist guidance should always be sought before use.^[4]

Important interactions and precautions with orlistat include:

• Orlistat is contraindicated with ciclosporin and must not be taken alongside it.^[4]

• Patients taking warfarin should have their INR monitored more closely, as orlistat may affect anticoagulant control.^[4]

• Levothyroxine should be taken at least four hours apart from orlistat, and thyroid function should be monitored.

• Caution is advised in patients taking antiepileptic medicines, as reduced absorption may affect seizure control.

• If severe diarrhoea or vomiting occurs, additional contraceptive precautions may be needed for those using oral contraceptives.

GLP-1 receptor agonists such as semaglutide are administered as a once-weekly subcutaneous injection. Patients are typically started on a low dose, which is gradually increased over several weeks to minimise gastrointestinal side effects. It is important to follow the dose escalation schedule provided by your prescriber and not to increase the dose more quickly than advised.

Experiencing these side effects? Our pharmacists can help you navigate them →

Important precautions with GLP-1 receptor agonists include:

• Patients also taking insulin or sulfonylureas are at increased risk of hypoglycaemia; dose adjustments to those medicines may be needed — discuss this with your prescriber.

• Persistent vomiting or diarrhoea can lead to dehydration and acute kidney injury; seek medical advice promptly if you are unable to keep fluids down.

• GLP-1 therapy should be used with caution in patients with a history of pancreatitis.

• People with diabetic retinopathy should be monitored, as rapid improvements in blood glucose control have been associated with worsening of this condition.

• Semaglutide and liraglutide must not be used during pregnancy or breastfeeding. For semaglutide, the SmPC advises stopping treatment at least two months before a planned pregnancy.

• Do not share injection pens with another person, even if the needle is changed.

• Store GLP-1 injection pens in the refrigerator as directed; refer to the specific product SmPC for guidance on out-of-fridge storage allowances.

General safety considerations:

• Never exceed the recommended dose — higher doses do not necessarily improve outcomes and increase the risk of adverse effects.

• Inform your GP or pharmacist of all other medications you are taking, as interactions can occur.

• Attend all follow-up appointments — weight, blood pressure, and tolerability should be monitored regularly.

Weight loss medications are generally intended for medium- to long-term use under medical supervision. Stopping abruptly without guidance may result in weight regain. Any concerns about dosing or tolerability should be discussed promptly with a healthcare professional rather than self-adjusting treatment.

If you experience a suspected side effect from any weight loss medicine, you can report it to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Eating habits and diet while taking weight loss pills

What you eat while taking weight loss medication plays a significant role in both the effectiveness of treatment and your overall experience of side effects.

For those taking orlistat, dietary fat intake must be carefully managed. The medication works by blocking fat absorption, meaning that consuming high-fat meals can lead to unpleasant gastrointestinal effects such as oily stools, urgency, and flatulence. NHS and NICE guidance recommends that fat intake should be spread evenly across meals and should not exceed approximately 30% of total daily calorie intake. Avoiding large, high-fat meals in a single sitting is particularly important for minimising these effects.

For individuals using GLP-1 receptor agonists, the medication itself reduces appetite and slows gastric emptying, which naturally leads to smaller portion sizes and reduced food intake. To help manage nausea — particularly during the dose escalation phase — it can be helpful to eat smaller, more frequent meals and to avoid large, greasy, or spicy meals. Maintaining adequate hydration is also important.

Not sure if this is normal? Chat with one of our pharmacists →

Regardless of which medication you are taking, focusing on nutritional quality rather than simply eating less will support sustainable weight loss and overall health. A balanced diet rich in:

• Vegetables, legumes, and wholegrains for fibre and micronutrients

• Lean proteins such as fish, poultry, eggs, and pulses to support satiety and muscle preservation

• Healthy unsaturated fats from sources such as olive oil, nuts, and avocado

• Adequate hydration — at least 6–8 glasses of water daily

...is recommended in line with the NHS Eatwell Guide.

It is advisable to avoid ultra-processed foods, sugary drinks, and excessive alcohol, all of which can undermine the benefits of medication. Eating slowly and mindfully can also help you recognise satiety cues more effectively, particularly when appetite is already reduced by GLP-1 therapy.

Orlistat may reduce the absorption of fat-soluble vitamins (A, D, E, and K). A daily multivitamin supplement, taken at least two hours apart from orlistat doses (for example, at bedtime), is often recommended.

Referral to a registered dietitian may be beneficial for personalised dietary planning, and many NHS weight management services include nutritional support as part of a structured programme.

Possible side effects and when to seek medical advice

Like all medications, weight loss medicines can cause side effects, and understanding these helps patients manage them effectively and know when to seek help.

With orlistat, the most commonly reported effects are gastrointestinal in nature and are directly related to unabsorbed fat passing through the digestive system. These include:

• Oily or fatty stools

• Increased frequency of bowel movements

• Flatulence and abdominal cramping

• Faecal urgency or, in some cases, incontinence

These effects are generally mild and tend to improve as patients adjust their fat intake. Rarely, orlistat has been associated with liver injury; seek medical advice if you develop jaundice, dark urine, or persistent itching.^[4] There have also been rare reports of renal stones (hyperoxaluria); seek advice if you experience loin pain or blood in the urine.^[4]

GLP-1 receptor agonists most commonly cause nausea, vomiting, diarrhoea, and constipation, particularly during the dose escalation phase.^[3][4] These effects usually diminish over time. Additional risks to be aware of include:

• Pancreatitis — seek urgent medical attention if you experience severe, persistent abdominal pain.

• Gallbladder disease — rapid weight loss can increase the risk of gallstones; symptoms include sharp upper abdominal pain, nausea, or jaundice.

• Acute kidney injury — persistent vomiting or diarrhoea can cause dehydration; seek prompt medical advice if you are unable to maintain fluid intake.

• Diabetic retinopathy — people with pre-existing diabetic eye disease should be monitored, as rapid changes in blood glucose control may affect this condition.

• Hypoglycaemia — if you are also taking insulin or a sulfonylurea, your risk of low blood sugar is increased; discuss dose adjustments with your prescriber.

Contact your GP promptly or seek urgent care if you experience:

• Severe or persistent abdominal pain

• Signs of an allergic reaction (rash, swelling, difficulty breathing)

• Mood changes or thoughts of self-harm — there have been reports of suicidal ideation in people using GLP-1 receptor agonists, which are currently under regulatory review by the MHRA and EMA; a causal link has not been confirmed, but you should seek urgent medical help if you experience such symptoms

• Symptoms of gallstones, such as sharp upper abdominal pain or jaundice

• Signs of liver problems (jaundice, dark urine, persistent itching) if taking orlistat

• Persistent vomiting or inability to maintain hydration

Patients with pre-existing cardiovascular or other significant medical conditions should discuss the individual benefits and risks of any weight loss medicine with their prescriber before starting treatment.

Suspected side effects from any weight loss medicine should be reported to the MHRA via the Yellow Card scheme at yellowcard.^[2]mhra.gov.uk.

NHS guidance on long-term weight management

The NHS and NICE emphasise that weight loss medication should always be viewed as one component of a broader, long-term weight management strategy — not a standalone solution. NICE guideline NG246 (2023) on obesity in adults outlines a tiered approach to weight management, beginning with lifestyle interventions and progressing to pharmacological or surgical options where clinically appropriate.^[1]

Response to treatment is assessed differently depending on the medicine:

• Orlistat: if a patient has not lost at least 5% of their initial body weight after 12 weeks of treatment, orlistat should generally be discontinued.

• Liraglutide (Saxenda): if a patient has not lost at least 5% of their initial body weight after 12 weeks at the full maintenance dose, treatment should be reassessed.^[4]

• Semaglutide (Wegovy): response is typically assessed at around six months on the maintenance dose, in line with the SmPC and local clinical guidance. Under current NICE recommendations, semaglutide for weight management is intended for use within specialist Tier 3 weight management services and for a maximum duration of two years.^[1][3] Commissioning arrangements may vary.

Long-term success in weight management is strongly associated with sustained behavioural change. The NHS Digital Weight Management Programme offers structured support, including access to dietitians, health coaches, and digital tools, for eligible adults in England. Access is typically via referral from a GP, pharmacist, or other healthcare professional; eligibility criteria apply.

Physical activity remains a cornerstone of long-term weight maintenance. UK Chief Medical Officers' guidelines recommend at least 150 minutes of moderate-intensity aerobic activity per week for adults, alongside muscle-strengthening activity on two or more days. Even modest increases in daily movement — such as brisk walking — can meaningfully support weight management outcomes.

It is important to recognise that obesity is a complex, chronic condition influenced by genetics, environment, psychology, and physiology. Patients should not feel stigmatised for requiring ongoing support or medication. Open, non-judgemental conversations with a GP, practice nurse, or specialist weight management team are encouraged.

For those who do not achieve adequate results with lifestyle changes and medication, bariatric surgery may be considered in line with NICE criteria — generally for adults with a BMI of 40 kg/m² or above, or 35 kg/m² or above with significant weight-related comorbidities. Lower thresholds may apply for people from certain ethnic backgrounds, and expedited surgical pathways may be considered for those with recent-onset type 2 diabetes. Bariatric surgery represents a further evidence-based option for long-term weight control where other approaches have not been sufficient.

Frequently Asked Questions